Clinical Trials Logo

Clinical Trial Summary

Adrenoleukodystrophy (X-ALD) is the most common genetic disorder of the brain white matter with an incidence of 1:14,700 births. It is caused by mutations in the ABCD1 gene, which encodes a transporter of very long-chain fatty acids (VCLFA) into the peroxisome for degradation. As a consequence VLCFA accumulate in tissues and plasma being the pathognomonic biomarker for diagnosis. The excess of VLCFA produces mitochondrial ROS and oxidative damage, a major factor driving X-ALD pathogenesis. Other key dysregulated pathways are energy production, mitochondrial biogenesis and respiration, proteostasis, and ER stress. Current therapeutic options are unsatisfactory, restricted to bone marrow transplant and gene therapy, for which most patients do not qualify. The encouraging results of plasma exchange (PE) with albumin replacement for Alzheimer's Disease prompted us to start this study. Our rationale is the following: In plasma, VLCFA are transported by lipoproteins and albumin. Albumin is the major transporter of fatty acids (FA) to the brain. ABCD1 deficiency induces inflammation and increases blood-brain barrier leakage, which could facilitate increased permeability to albumin. We posit that replacement of albumin would lower VLCFA levels in plasma through peripheral sink mechanisms, diminishing the quantity of VLCFA reaching the brain, and would prevent lipid peroxidation. A pilot proof-of-concept study in 5 X-ALD patients will be carried out to replace endogenous albumin through PE applied, once a week the first month and monthly for 5 months. A 6 months follow-up after the end of the treatment will be carried out.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04303416
Study type Interventional
Source Onofre, Aurora Pujol, M.D.
Contact
Status Completed
Phase Phase 2/Phase 3
Start date March 9, 2020
Completion date September 13, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT02254863 - UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells Phase 1
Completed NCT00383448 - HSCT for High Risk Inherited Inborn Errors Phase 2
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Completed NCT02961803 - MD1003-AMN MD1003 in Adrenomyeloneuropathy Phase 2/Phase 3
Withdrawn NCT02948062 - Early Diagnosis Of Childhood Cerebral ALD
Completed NCT02952482 - Newborn Screening for Adrenoleukodystrophy
Recruiting NCT03789721 - Adrenoleukodystrophy National Registry Study
Terminated NCT00545597 - A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy Phase 3
Completed NCT03513328 - Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Phase 1/Phase 2
Active, not recruiting NCT02699190 - LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Recruiting NCT02559830 - Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy Phase 1/Phase 2
Recruiting NCT00278044 - Clinical Study and Gene Mutation Analysis of Adrenoleukodystrophy in Taiwanese Children N/A
Completed NCT00176904 - Stem Cell Transplant for Inborn Errors of Metabolism Phase 2/Phase 3
Completed NCT00007020 - Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid Phase 3
Active, not recruiting NCT03231878 - A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients. Phase 2/Phase 3
Recruiting NCT03047369 - The Myelin Disorders Biorepository Project
Recruiting NCT04925349 - Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy, Metachromatic Leukodystrophy and Adult Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia
Active, not recruiting NCT00005900 - Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation N/A
Completed NCT00004450 - Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy N/A
Recruiting NCT04090268 - Precision Exercise in Children With Malignant Hemopathies N/A